HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hartz, R. S. Articles by Michaelis, L. L. Search for Related Content PubMed PubMed Citation Articles by Hartz, R. S. Articles by Michaelis, L. L.

The Journal of Thoracic and Cardiovascular Surgery, Vol 91, 910-917, Copyright © 1986 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

An eight-year experience with porcine bioprosthetic cardiac valves

RS Hartz, EB Fisher, B Finkelmeier, A DeBoer, JH Sanders Jr, JM Moran and LL Michaelis

A total of 589 porcine bioprostheses were implanted in 509 patients from January, 1976, through December, 1983. Of the valves implanted, 390 were Hancock and 199 were Carpentier-Edwards. A total of 1,633 patient-years was accrued, with a mean follow-up of 38 months per patient. Two hundred eight patients had aortic valve replacement, 209 had mitral valve replacement, and 79 had multiple valve replacements, of which 46 were aortic and mitral replacements. The mortality for isolated aortic valve replacement was 5.8%; for isolated mitral replacement, 8.6%, and for all patients, 10.9%. Late mortality was 3.9% per patient-year. The actuarial survival rate at 5 years was 79% for aortic, 68% for mitral, and 76% for aortic-mitral valve replacement. There were 12 thromboembolic events (0.73% per patient-year). Two episodes occurred in patients with an aortic bioprosthesis, nine in patients with a porcine mitral valve, and one in a patient with mitral and tricuspid bioprosthetic valves. The probability of remaining free of thromboembolism at 5 years was 99% for the group having aortic valve replacement, 93% for those having mitral replacement, and 100% for the group having aortic-mitral valve replacements. Thirteen episodes of endocarditis occurred (0.8% per patient-year). Seven of the 13 patients died as a direct result of endocarditis. The probability of remaining free of prosthetic endocarditis at 5 years was 97% for the aortic valve replacement group, 95% for the mitral group, and 97% for the aortic- mitral group. There were 20 instances of xenograft failure (1.2% per patient-year). The probability of remaining free of valve failure at 5 years was 96% for the aortic valve replacement group, 93% for the mitral group, and 93% for the aortic-mitral replacement group. Primary tissue failure of a prosthesis occurred in seven patients, all with Hancock valves (0.43% per patient-year). As yet there has been no primary tissue failure of the Carpentier-Edwards prosthesis. There also appears to be a lower incidence of thromboembolism (Edwards, 0.3% per patient-year; Hancock, 0.8% per patient-year) and endocarditis (Edwards, 0.6% per patient-year; Hancock, 1.0% per patient-year). The low incidence of complications with the porcine bioprosthetic valve, especially the Carpentier-Edwards, encourages us to recommend its continued use, especially in situations in which anticoagulation is contraindicated.

This article has been cited by other articles:

				S. Talwar, A. Mathur, S. K. Choudhary, R. Singh, and A. S. Kumar Aortic Valve Replacement With Mitral Valve Repair Compared With Combined Aortic and Mitral Valve Replacement Ann. Thorac. Surg., October 1, 2007; 84(4): 1219 - 1225. [Abstract] [Full Text] [PDF]

				M. Brueck, W. Kramer, P. Vogt, N. Steinert, P. Roth, G. Gorlach, M. Schonburg, and M. C. Heidt Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 108 - 112. [Abstract] [Full Text] [PDF]

				A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF]

				T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study Circulation, August 3, 2004; 110(5): 496 - 500. [Abstract] [Full Text] [PDF]

				T. Kazui, H. Kin, H. Izumoto, T. Nakajima, K. Ishihara, and K. Kawazoe Combined Aortic and Mitral Valve Repair Asian Cardiovasc Thorac Ann, December 1, 2003; 11(4): 319 - 322. [Abstract] [Full Text] [PDF]

				L. V. Del Priore, O. Ishida, E. W. Johnson, Y. Sheng, D. B. Jacoby, L. Geng, T. H. Tezel, and H. J. Kaplan Triple Immune Suppression Increases Short-Term Survival of Porcine Fetal Retinal Pigment Epithelium Xenografts Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 4044 - 4053. [Abstract] [Full Text] [PDF]

				A. M. Gillinov, E. H. Blackstone, D. M. Cosgrove III, J. White, P. Kerr, A. Marullo, P. M. McCarthy, and B. W. Lytle Mitral valve repair with aortic valve replacement is superior to double valve replacement J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1372 - 1387. [Abstract] [Full Text] [PDF]

				A. M. Gillinov, E. H. Blackstone, J. White, M. Howard, R. Ahkrass, A. Marullo, and D. M. Cosgrove Durability of combined aortic and mitral valve repair Ann. Thorac. Surg., July 1, 2001; 72(1): 20 - 27. [Abstract] [Full Text] [PDF]

				T. A. Orszulak, H. V. Schaff, C. J. Mullany, B. J. Anderson, D. M. Ilstrup, F. J. Puga, and G. K. Danielson Risk of Thromboembolism With the Aortic Carpentier-Edwards Bioprosthesis Ann. Thorac. Surg., February 1, 1995; 59(2): 462 - 468. [Abstract] [Full Text]